当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Partial nephrectomy for the treatment of translocation renal cell carcinoma.

Partial nephrectomy for the treatment of translocation renal cell carcinoma.

Abstract：

BACKGROUND:The aim of this study was to evaluate the outcome of patients with translocation renal cell carcinoma (RCC) treated with partial nephrectomy. PATIENTS AND METHODS:Our institutional review board-approved renal mass registry was queried for patients who underwent partial nephrectomy for a pathologically confirmed translocation RCC. We describe the demographic, clinical, pathological, and follow-up data for this series of patients. RESULTS:Between 2003 and 2013, 1897 patients with RCC were treated at our institution with a radical or partial nephrectomy. In total, 10 (0.5%) patients were diagnosed with a translocation RCC. Of these patients, 4 (40%) underwent treatment with partial nephrectomy for an incidentally detected small renal mass (mean imaging diameter, 2.6 cm [range, 1.0-4.2 cm]). During a mean follow-up of 37 months (range, 8-81 months), all patients were alive without evidence of disease. CONCLUSION:At short-term follow-up, partial nephrectomy appears to be an effective treatment option for patients with small translocation RCCs. Larger studies are required to more extensively investigate the optimal treatment of these potentially aggressive tumors.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Gorin MA,Ball MW,Pierorazio PM,Argani P,Allaf ME

doi

10.1016/j.clgc.2014.12.008

subject

Has Abstract

pub_date

2015-06-01 00:00:00

pages

e199-201

issue

3

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(14)00282-1

journal_volume

13

pub_type

杂志文章

相关文献

Clinical Genitourinary Cancer文献大全
  • Histopathologic Characteristics of Upper Tract Urothelial Carcinoma With an Emphasis on Their Effect on Cancer Survival: A Single-Institute Experience With 305 Patients With Long-Term Follow-Up.

    abstract：INTRODUCTION:Tumor stage and grade represent the best established predictors for the prognosis of upper tract urothelial carcinoma (UTUC). However, controversies still exist regarding the role of tumor necrosis, location, and multifocality in the prognosis of UTUC. We share our experience with 305 patients, reporting o...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.04.017

    authors： Elawdy MM,Taha DE,Elbaset MA,Abouelkheir RT,Osman Y

    更新日期：2016-12-01 00:00:00

  • Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients.

    abstract：BACKGROUND:Enzalutamide is active in advanced castration-resistant prostate cancer (CRPC) patients, in whom it has shown to be able to increase survival. We report the enzalutamide effect on primary prostate tumors, assessed by changes of metabolic tumor activity detected by (18)F-fluorocholine-positron emission tomogr...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.03.004

    authors： Caffo O,Maines F,Donner D,Veccia A,Chierichetti F,Galligioni E

    更新日期：2014-10-01 00:00:00

  • Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience.

    abstract：BACKGROUND:First-line PD-inhibition in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer represents a novel clinical setting, with uncertainty concerning second-line outcomes. Specifying second-line treatment and outcomes will provide guidance in this new sequence. We performed a retro...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.10.001

    authors： Hsu MM,Xia Y,Troxel A,Delbeau D,Francese K,Leis D,Shepherd D,Balar AV

    更新日期：2020-06-01 00:00:00

  • A phase II study of depsipeptide in refractory metastatic renal cell cancer.

    abstract：BACKGROUND:Therapeutic options for renal cell cancer are inadequate. Depsipeptide is a histone deacetylase inhibitor with promising preclinical and early clinical activity. PATIENTS AND METHODS:Patients with refractory renal cell cancer with normal organ function and no history of significant cardiovascular disease we...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2006.n.018

    authors： Stadler WM,Margolin K,Ferber S,McCulloch W,Thompson JA

    更新日期：2006-06-01 00:00:00

  • Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.

    abstract：BACKGROUND:Serum testosterone measurement is recommended to assess the efficacy of androgen deprivation therapy (ADT) and to diagnose castration resistance in patients with prostate cancer (PCa). Currently, the accepted castrate level of serum testosterone is 50 ng/dL. Liquid chromatography and tandem mass spectrometry...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.10.025

    authors： Morote J,Comas I,Planas J,Maldonado X,Celma A,Placer J,Ferrer R,Carles J,Regis L

    更新日期：2018-04-01 00:00:00

  • Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

    abstract：BACKGROUND:Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identi...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2018.02.016

    authors： Angelergues A,Efstathiou E,Gyftaki R,Wysocki PJ,Lainez N,Gonzalez I,Castellano DE,Ozguroglu M,Carbonero IG,Flechon A,Borrega P,Guillot A,Balea BC,Le Moulec S,Esteban E,Munarriz J,Rubio G,Birtle AJ,Delanoy N,Bellmunt

    更新日期：2018-08-01 00:00:00

  • Eosinophilic rash secondary to temsirolimus.

    abstract：:We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinoph...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.019

    authors： Gandhi M,Kuzel T,Lacouture M

    更新日期：2009-08-01 00:00:00

  • Identification of Differential Patterns of Oxidative Biomarkers in Prostate Cancer Progression.

    abstract：INTRODUCTION:Oxidative stress has been found to be associated with the progression of prostate cancer (PCa); however, human studies which identify differential roles of each oxidation pathway in PCa progression are lacking. We aimed to identify which oxidative stress markers, specifically lipid and global oxidation and...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.014

    authors： Wu T,Kasper S,Wong RM,Bracken B

    更新日期：2020-04-01 00:00:00

  • The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.

    abstract：BACKGROUND:Abiraterone and enzalutamide are 2 novel androgen receptor (AR)-targeting therapies that improve survival in patients with metastatic castration-resistant prostate cancer. The factors that predict abiraterone and enzalutamide response are lacking. The objective of the present study was to determine whether t...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.03.021

    authors： Hung J,Taylor AR,Divine GW,Hafron JM,Hwang C

    更新日期：2016-10-01 00:00:00

  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy.

    abstract：:Effective options are lacking for progressive castration-refractory prostate cancer (CRPC) after conventional chemotherapy. Sunitinib is an orally administered multitargeted tyrosine kinase inhibitor that is approved multinationally for renal cell carcinoma and gastrointestinal stromal tumors. A phase II trial was con...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2008.n.023

    authors： Sonpavde G,Hutson TE,Berry WR,Boehm KA,Asmar L

    更新日期：2008-09-01 00:00:00

  • Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.

    abstract：BACKGROUND:In the phase III axitinib second-line (AXIS) trial, axitinib significantly prolonged progression-free survival (PFS) versus sorafenib in patients with previously treated metastatic renal cell carcinoma (mRCC). Analyses of associations between germline single-nucleotide polymorphisms (SNPs) and outcomes are r...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.clgc.2015.02.007

    authors： Escudier B,Rini BI,Motzer RJ,Tarazi J,Kim S,Huang X,Rosbrook B,English PA,Loomis AK,Williams JA

    更新日期：2015-08-01 00:00:00

  • Primary extraosseous ewing sarcoma of the kidney with level III inferior vena cava thrombus.

    abstract：:Ewing sarcoma typically presents as a skeletal-based tumor, with rare instances of peripheral primitive neuroectodermal tumor (PNET) arising in the soft tissues. Few examples of organ-based PNETs have been previously described in the literature. These tumors are exceedingly rare as a primary renal neoplasm. To our kno...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.3816/CGC.2009.n.032

    authors： Fergany AF,Dhar N,Budd GT,Skacel M,Garcia JA

    更新日期：2009-10-01 00:00:00

  • Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer.

    abstract：BACKGROUND:The most common presenting symptom of bladder cancer (BCa) is hematuria. The present study was designed to define whether patients taking antiplatelet and/or anticoagulant drugs might experience hematuria at an earlier stage or grade of BCa. PATIENTS AND METHODS:The data from 1532 consecutive patients who p...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2015.08.003

    authors： Moschini M,Karnes RJ,Suardi N,Bianchi M,Pellucchi F,Rocchini L,Damiano R,Serretta V,Salonia A,Montorsi F,Briganti A,Colombo R

    更新日期：2016-06-01 00:00:00

  • Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma.

    abstract：INTRODUCTION:The objective of this study was to determine the effectiveness and safety of pazopanib in patients with intermediate-risk advanced/metastatic renal cell carcinoma in the PRINCIPAL study (NCT01649778). PATIENTS AND METHODS:Patients had clear-cell advanced/metastatic renal cell carcinoma and met intermediat...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.01.018

    authors： Procopio G,Bamias A,Schmidinger M,Hawkins R,Sánchez AR,Estevez SV,Srihari N,Kalofonos H,Bono P,Pisal CB,Hirschberg Y,Dezzani L,Ahmad Q,Rodriguez CS,Jonasch E

    更新日期：2019-06-01 00:00:00

  • Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.

    abstract：INTRODUCTION:Clinical T1 (cT1) bladder cancer is associated with high rates of recurrence, upstaging, and progression. Guidelines recommend that these patients be treated with adjuvant intravesical Bacillus Calmette-Guérin immunotherapy (BCG) or upfront radical cystectomy (RC). We analyzed the National Cancer Database ...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.01.007

    authors： Balakrishnan AS,Washington SL 3rd,Meng MV,Porten SP

    更新日期：2019-06-01 00:00:00

  • Small renal masses managed with active surveillance: predictors of tumor growth rate after long-term follow-up.

    abstract：BACKGROUND:The purpose of the study was to evaluate the relationships between the patients' clinical characteristics and the growth pattern of SRMs, and to investigate the predictive factors of tumor growth rates in patients initially managed with AS. MATERIALS AND METHODS:We retrospectively reviewed data from our pro...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2014.08.006

    authors： Schiavina R,Borghesi M,Dababneh H,Bianchi L,Longhi B,Diazzi D,Monti C,La Manna G,Martorana G,Brunocilla E

    更新日期：2015-04-01 00:00:00

  • Racial and Socioeconomic Disparities in Bladder Cancer Survival: Analysis of the California Cancer Registry.

    abstract：PURPOSE:To examine the California Cancer Registry (CCR) for bladder cancer survival disparities based on race, socioeconomic status (SES), and insurance in California patients. PATIENTS AND METHODS:The CCR was queried for bladder cancer cases in California from 1988 to 2012. The primary outcome was disease-specific su...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.05.008

    authors： Sung JM,Martin JW,Jefferson FA,Sidhom DA,Piranviseh K,Huang M,Nguyen N,Chang J,Ziogas A,Anton-Culver H,Youssef RF

    更新日期：2019-10-01 00:00:00

  • Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model.

    abstract：BACKGROUND:Tumor location in bladder neck has reported to be a prognostic factor for non-muscle-invasive bladder cancer (NMIBC). We investigated the impact of bladder neck involvement (BNI) on recurrence in NMIBC using time-dependent covariate analysis. PATIENTS AND METHODS:We enrolled 585 Japanese patients who underw...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.10.005

    authors： Waseda Y,Kobayashi S,Kanda E,Yokoyama M,Ishioka J,Matsuoka Y,Saito K,Fujii Y

    更新日期：2020-04-01 00:00:00

  • Hyperprogressive Disease in Patients With Urothelial Carcinoma or Renal Cell Carcinoma Treated With PD-1/PD-L1 Inhibitors.

    abstract：BACKGROUND:A rapid progression pattern called hyperprogressive disease (HPD) has been observed during early cycles of programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy. Data regarding HPD in patients with genitourinary cancer are limited. PATIENTS AND METHODS:We included 203 pa...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.009

    authors： Hwang I,Park I,Yoon SK,Lee JL

    更新日期：2020-04-01 00:00:00

  • Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy.

    abstract：BACKGROUND:Venous thromboembolic events (VTEs) frequently occur in cancer patients. Risk assessment models (RAMs) for cancer-associated thrombosis have been proposed. However, advanced urinary tract cancer (aUTC) was not adequately represented in these models. We studied the incidence of VTEs, the risk factors, and the...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.12.021

    authors： Bamias A,Tzannis K,Dimitriadis I,Tsironis G,Papatheorodidi AM,Tsiara A,Fragkoulis C,Xirokosta A,Barbarousi D,Papadopoulos G,Zakopoulou R,Varkarakis I,Mitsogiannis I,Adamakis I,Alamanis C,Stravodimos K,Papatsoris AG,Dell

    更新日期：2020-08-01 00:00:00

  • Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.

    abstract：BACKGROUND:Piritrexim is reported to have a response rate of 38% in patients with chemotherapy-naive disease and 23% for second-line therapy after chemotherapy failure. We report the results of a multiinstitutional, open-label, 2-stage, phase II study that further evaluates oral piritrexim in patients with urothelial c...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.3816/CGC.2008.n.005

    authors： Lassiter LK,Tummala MK,Hussain MH,Stadler WM,Petrylak DP,Carducci MA

    更新日期：2008-03-01 00:00:00

  • Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.

    abstract：BACKGROUND:The purpose of this study was to compare the efficacy of 2 bacillus Calmette-Guérin (BCG) strains, BCG-Tice and BCG-Moreau, in the treatment of non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS:We retrospectively reviewed clinical data from patients treated with BCG for NMIBC at 3 academic c...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2019.10.021

    authors： D'Andrea D,Soria F,Abufaraj M,Pones M,Gontero P,Machado AT,Waksman R,Enikeev DV,Glybochko PV,Adonias SP,Nahas WC,Shariat SF,Chade DC

    更新日期：2020-02-01 00:00:00

  • Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study.

    abstract：BACKGROUND:The present study tested cancer-specific (CSM) and overall mortality (OM) after partial cystectomy (PC) for variant histology bladder cancer (non-urothelial carcinoma of the urinary bladder UCUB), relative to UCUB and relative to radical cystectomy (RC). MATERIALS AND METHODS:Within the Surveillance, Epidem...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.10.016

    authors： Luzzago S,Palumbo C,Rosiello G,Knipper S,Pecoraro A,Deuker M,Mistretta FA,Tian Z,Musi G,Montanari E,Shariat SF,Saad F,Briganti A,de Cobelli O,Karakiewicz PI

    更新日期：2020-04-01 00:00:00

  • Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.

    abstract：BACKGROUND:Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS:In patients with SqD muscle-invas...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.01.024

    authors： Buisan O,Orsola A,Oliveira M,Martinez R,Etxaniz O,Areal J,Ibarz L

    更新日期：2017-08-01 00:00:00

  • Utilization of Pelvic Lymph Node Dissection for Patients With Low-Risk Prostate Cancer Treated With Robot-Assisted Radical Prostatectomy.

    abstract：INTRODUCTION:Pelvic lymph node dissection (PLND) is not recommended for low-risk prostate cancer (PCa) patients. However, the rate of PLND in this population is unknown. METHODS:We queried the National Cancer Data Base for PCa patients who underwent robot-assisted radical prostatectomy from 2010 to 2013 and stratified...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2017.05.013

    authors： Modi PK,Bock M,Kim S,Singer EA,Parikh RR

    更新日期：2017-12-01 00:00:00

  • A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.

    abstract：UNLABELLED:The present multicenter phase II study evaluated the efficacy and safety of weekly docetaxel as second-line chemotherapy for metastatic urothelial carcinoma. Weekly docetaxel was well tolerated but demonstrated modest activity, with a response rate of 6%, a median progression-free survival (PFS) of 1.4 month...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.clgc.2015.09.008

    authors： Kim YS,Lee SI,Park SH,Park S,Hwang IG,Lee SC,Sun JM,Lee J,Lim HY

    更新日期：2016-02-01 00:00:00

  • New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

    abstract：:Systemic treatment of men with metastatic prostate cancer is rapidly evolving. Androgen deprivation therapy remains the first-line treatment for advanced disease and the backbone of sequential strategies. For patients with extensive metastatic disease the addition of docetaxel markedly improves survival. In case patie...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clgc.2015.01.008

    authors： van Dodewaard-de Jong JM,Verheul HMW,Bloemendal HJ,de Klerk JMH,Carducci MA,van den Eertwegh AJM

    更新日期：2015-08-01 00:00:00

  • Clinical Significance of Subclassification of Papillary Renal Cell Carcinoma: Comparison of Clinicopathologic Parameters and Oncologic Outcomes Between Papillary Histologic Subtypes 1 and 2 Using the Korean Renal Cell Carcinoma Database.

    abstract：INTRODUCTION:The aims of the present study were to compare the clinicopathologic characteristics between type 1 and type 2 papillary renal cell carcinoma (pRCC) and to evaluate the effect of the subclassification of pRCC on the oncologic outcomes after surgery. MATERIALS AND METHODS:The records of 274 patients with pR...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2016.07.020

    authors： Ha YS,Chung JW,Choi SH,Lee JN,Kim HT,Kim TH,Chung SK,Byun SS,Hwang EC,Kang SH,Hong SH,Chung J,Kwak C,Kim YJ,Kwon TG,Korean Renal Cell Carcinoma Study Group.

    更新日期：2017-04-01 00:00:00

  • Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.

    abstract：BACKGROUND:The objective of this study was to determine the outcomes of young adults with kidney cancer treated during the targeted therapy era and evaluate the impact of young age on survival. MATERIALS AND METHODS:We reviewed the records from 445 patients younger than 55 years with kidney cancer at a single institut...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2019.09.012

    authors： Sierra PS,Cordeiro MD,Albuquerque EV,Bastos DA,Bonadio RC,Sarkis AS,Cavalcante A,Pontes J Jr,Coelho RF,Nahas WC

    更新日期：2020-04-01 00:00:00

  • Nivolumab Is a Cost-Effective Second-Line Treatment for Metastatic Renal-Cell Carcinoma.

    abstract：INTRODUCTION:The introduction of active new agents, such as small molecules and checkpoint inhibitors, for the treatment of metastatic renal-cell cancer (mRCC) is associated with a relevant increase in costs, and it is therefore important to strike a balance between the costs of treatment and the added value represente...

    journal_title：Clinical genitourinary cancer

    pub_type： 杂志文章

    doi：10.1016/j.clgc.2018.02.006

    authors： Giuliani J,Bonetti A

    更新日期：2018-06-01 00:00:00